(Zhou Xuejin, a reporter from the Peoples Daily Health Client) On November 11, the double -formation medicine industry, which was known as the "ten times bull stocks", fell again at 27.7 yuan.Compared with the highest point of 40.98 yuan per share this year, it has fallen by one -third.
The latest three quarterly reports released by Shuangcheng Pharmaceuticals show that in the first three quarters of this year, the companys revenue and mothers net profit both fell sharply.EssenceSince the resumption of trading in September, Shuangcheng Pharmaceutical has issued 16 risk prompts.
Public information shows that was established in 2000, specializing in the production of chemical synthetic peptide drugs, and the production of polypeptide drugs, andSales and R & D, the main products include new thymus method for injection, growth of growth for injection, and injection for injection and injection, and injector injection, and Yitar Pantpan peptide injection, and listed on the Shenzhen Stock Exchanges small and medium -sized board on August 8, 2012.
Since the beginning of this year, the stock price of Shuangcheng Pharmaceutical has risen from the low point of 4 yuan/share on July 25, which once touched the highest point of 40.98 yuan/share, so it was called "Ten times bull stocks ".A reporter from the Peoples Daily Health Client found that since September, Shuangcheng Pharmaceutical has achieved more than 20 daily limit boards.
Behind the creation of "bull stocks" is a planned asset reorganization.On August 27 this year, Shuangcheng Pharmaceutical announced the planning of major assets to reorganize and suspend trading.On September 10, Shuangcheng Pharmaceutical issued an asset reorganization plan, announcing the purchase of 100%of Ningbo Ora Semiconductor Co., Ltd.Beginning on September 11, the stock price of Shuangcheng Pharmaceuticals opened a continuous daily limit model, and once, the stock price had a daily limit of 14 consecutive trading days.
However, behind the "ten times bull stocks", Shuangcheng Pharmaceutical has suffered a lot of losses since its listing.At present, its cumulative losses have not made up the amount of losses exceeding one -third of the total shareholding.On October 30, Shuangcheng Pharmaceutical released the third quarter of the 2024th report. In the third quarter of 2024, the companys revenue was 320.669 million yuan, a year -on -year decrease of 25.83%.EssenceIn the first three quarters, the companys operating income was 127 million yuan, a decrease of 30.34%year -on -year, and the net profit attributable to the mother was a loss of 37.877 million yuan.
On November 9, Shuangcheng Pharmaceutical again issued the progress and risk reminder announcement on major asset reorganization.According to the relevant provisions of the "Shenzhen Stock Exchange Stock Listing Rules", the net profit after 2024 companies cannot achieve total profit, net profit, or deducting non -recurring gains and losses is positive, and the operating income after deducting is less than 300 million yuanThe companys stock will be warned by the Shenzhen Stock Exchange.
